Clostridium difficile spores: A major threat to the hospital environment

Future Microbiology

Volumn 9, Issue 4, 2014, Pages 475-486

  Barra Carrasco, Jonathan ^a   Paredes Sabja, Daniel ^a,b  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Clostridium difficile; exosporium; nosocomial diarrhea; spores; sporulation

Indexed keywords

DISINFECTANT AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL SPORE; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE TRANSMISSION; GERMINATION; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; MORPHOTYPE; PRIORITY JOURNAL; R FACTOR; REVIEW; SPOROGENESIS; CLOSTRIDIUM INFECTIONS; COLON; CROSS INFECTION; DIARRHEA; EPIDEMIOLOGY; HETEROZYGOTE; HOSPITAL; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; TRANSMISSION;

CARRIER STATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLON; CROSS INFECTION; DIARRHEA; DISEASE TRANSMISSION, INFECTIOUS; HOSPITALS; SPORES, BACTERIAL;

EID: 84900333912     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.2     Document Type: Review

References (106)

1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol 7(7), 526-536 (2009).
2. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J. Gastroenterol. 15(13), 1554-1580 (2009).
3. Kato H, Ito Y, van den Berg RJ, Kuijper EJ, Arakawa Y. First isolation of Clostridium difficile 027 in Japan. Euro Surveill. 12(1), E070111.3 (2007).
4. Borgmann S, Kist M, Jakobiak T et al. Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany. Euro Surveill. 13(49), pii: 19057 (2008).
5. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12(Suppl. 6), 2-18 (2006).
6. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353(23), 2442-2449 (2005).
7. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353(23), 2433-2441 (2005).
8. Labbe AC, Poirier L, Maccannell D et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob. Agents Chemother. 52(9), 3180-3187 (2008).
9. Miller M, Gravel D, Mulvey M et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50(2), 194-201 (2010).
10. Walker AS, Eyre DW, Wyllie DH et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin. Infect. Dis. 56(11), 1589-1600 (2013).
11. Dingle KE, Griffiths D, Didelot X et al. Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS ONE 6(5), e19993 (2011).
12. Stabler RA, He M, Dawson L et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 10(9), R102 (2009).
13. Brouwer MS, Warburton PJ, Roberts AP, Mullany P, Allan E. Genetic organisation, mobility and predicted functions of genes on integrated, mobile genetic elements in sequenced strains of Clostridium difficile. PLoS ONE 6(8), e23014 (2011).
14. Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW. Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J. Med. Microbiol. 61(Pt 1), 49-56 (2012).
15. He M, Miyajima F, Roberts P et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 45(1), 109-113 (2013).
16. Carter GP, Douce GR, Govind R et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 7(10), e1002317 (2011).
17. Cartman ST, Kelly ML, Heeg D, Heap JT, Minton NP. Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production. Appl. Environ. Microbiol. 78(13), 4683-4690 (2012).
18. Stabler RA, Valiente E, Dawson LF, He M, Parkhill J, Wren BW. In-depth genetic analysis of Clostridium difficile PCR-ribotype 027 strains reveals high genome fluidity including point mutations and inversions. Gut Microbes 1(4), 269-276 (2010).
19. Schirmer J, Aktories K. Large clostridial cytotoxins: cellular biology of Rho/Ras-glucosylating toxins. Biochim. Biophys. Acta 1673(1-2), 66-74 (2004).
20. Davies AH, Roberts AK, Shone CC, Acharya KR. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem. J. 436(3), 517-526 (2011).
21. Papatheodorou P, Carette JE, Bell GW et al. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc. Natl Acad. Sci. USA 108(39), 16422-16427 (2011).
22. Schwan C, Stecher B, Tzivelekidis T et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 5(10), e1000626 (2009).
23. Sarker MR, Paredes-Sabja D. Molecular basis of early stages of Clostridium difficile infection: germination and colonization. Future Microbiol. 7(8), 933 (2012).
24. Paredes-Sabja D, Sarker MR. Adherence of Clostridium difficile spores to Caco-2 cells in culture. J. Med. Microbiol. 61(9), 1208-1218 (2012).
25. Paredes-Sabja D, Cofre-Araneda G, Brito-Silva C, Pizarro-Guajardo M, Sarker MR. Clostridium difficile spore-macrophage interactions: spore survival. PLoS ONE 7(8), e43635 (2012).
26. Eyre DW, Cule ML, Wilson DJ et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N. Engl. J. Med. 369(13), 1195-1205 (2013).
27. Giel JL, Sorg JA, Sonenshein AL, Zhu J. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS ONE 5(1), e8740 (2010).
28. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 20(7), 313-319 (2012).
29. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect. Control Hosp. Epidemiol. 31(1), 21-27 (2010).
30. Oka K, Osaki T, Hanawa T et al. Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases. J. Clin. Microbiol. 50(3), 915-921 (2012).
31. Paredes-Sabja D, Sarker MR. Clostridium perfringens sporulation and its relevance to pathogenesis. Future Microbiol. 4, 519-525 (2009).
32. Deakin LJ, Clare S, Fagan RP et al. Clostridium difficile spo0A gene is a persistence and transmission factor. Infect. Immun. 80(8), 2704-2711 (2012).
33. Janoir C, Deneve C, Bouttier S et al. Insights into the adaptive strategies and pathogenesis of Clostridium difficile from in vivo transcriptomics. Infect. Immun. 81(10), 3757-3769 (2013).
34. Lawley TD, Croucher NJ, Yu L et al. Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J. Bacteriol. 191(17), 5377-5386 (2009).
35. Permpoonpattana P, Tolls EH, Nadem R, Tan S, Brisson A, Cutting SM. Surface layers of Clostridium difficile endospores. J. Bacteriol. 193(23), 6461-6470 (2011).
36. Hoch JA, Varughese KI. Keeping signals straight in phosphore lay signal transduction. J. Bacteriol. 183(17), 4941-4949 (2001).
37. Fimlaid KA, Bond JP, Schutz KC et al. Global analysis of the sporulation pathway of Clostridium difficile. PLoS Genet. 9(8), e1003660 (2013).
38. Pereira FC, Saujet L, Tome AR et al. The spore differentiation pathway in the enteric pathogen Clostridium difficile. PLoS Genet. 9(10), e1003782 (2013).
39. Saujet L, Pereira FC, Serrano M et al. Genome-wide analysis of cell type-specific gene transcription during spore formation in Clostridium difficile. PLoS Genet. 9(10), e1003756 (2013).
40. Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infection. J. Infect. Dis. 207(10), 1498-1504 (2013).
41. Boyanton BL Jr, Sural P, Loomis CR et al. Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. J. Clin. Microbiol. 50(3), 640-645 (2012).
42. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55(Suppl. 2), S162-S169 (2012).
43. Schlecht U, St Onge RP, Walther T, Francois JM, Davis RW. Cationic amphiphilic drugs are potent inhibitors of yeast sporulation. PLoS ONE 7(8), e42853 (2012).
44. Guerrero DM, Nerandzic MM, Jury LA, Jinno S, Chang S, Donskey CJ. Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium difficile infection and with environmental surfaces in their rooms. Am. J. Infect. Control. 40(6), 556-558 (2012).
45. Sunkesula VC, Kundrapu S, Jury LA, Deshpande A, Sethi AK, Donskey CJ. Potential for transmission of spores by patients awaiting laboratory testing to confirm suspected Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 34(3), 306-308 (2013).
46. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320(4), 204-210 (1989).
47. Bobulsky GS, Al-Nassir WN, Riggs MM, Sethi AK, Donskey CJ. Clostridium difficile skin contamination in patients with C. difficile-associated disease. Clin. Infect. Dis. 46(3), 447-450 (2008).
48. Jury LA, Sitzlar B, Kundrapu S et al. Outpatient healthcare settings and transmission of Clostridium difficile. PLoS ONE 8(7), e70175 (2013).
49. Fawley WN, Wilcox MH. Molecular epidemiology of endemic Clostridium difficile infection. Epidemiol. Infect. 126(3), 343-350 (2001).
50. Fawley WN, Freeman J, Wilcox MH. Evidence to support the existence of subgroups within the UK epidemic Clostridium difficile strain (PCR ribotype 1). J. Hosp. Infect. 54(1), 74-77 (2003).
51. Roberts K, Smith CF, Snelling AM ,Aerial dissemination of Clostridium difficile spores. BMC Infect. Dis. 8, 7 (2008).
52. Fekety R, Kim KH, Batts DH et al. Studies on the epidemiology of antibiotic-associated Clostridium difficile colitis. Am. J. Clin. Nutr. 33(Suppl. 11), 2527-2532 (1980).
53. Fekety R, Kim KH, Brown D, Batts DH, Cudmore M, Silva J Jr. Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am. J. Med. 70(4), 906-908 (1981).
54. Kim KH, Fekety R, Batts DH et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J. Infect. Dis. 143(1), 42-50 (1981).
55. Dawson LF, Valiente E, Donahue EH, Birchenough G, Wren BW. Hypervirulent Clostridium difficile PCR-ribotypes exhibit resistance to widely used disinfectants. PLoS ONE 6(10), e25754 (2011).
56. Perez J, Springthorpe VS, Sattar SA. Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile. J. AOAC Int. 94(2), 618-626 (2011).
57. Lawley TD, Clare S, Deakin LJ et al. Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Appl. Environ. Microbiol. 76(20), 6895-6900 (2010).
58. Wullt M, Odenholt I, Walder M. Activity of three disinfectants and acidified nitrite against Clostridium difficile spores. Infect. Control Hosp. Epidemiol. 24(10), 765-768 (2003).
59. Cowan RE, Manning AP, Ayliffe GA et al. Aldehyde disinfectants and health in endoscopy units. British Society of Gastroenterology Endoscopy Committee. Gut 34(11), 1641-1645 (1993).
60. Barbut F, Yezli S, Otter JA. Activity in vitro of hydrogen peroxide vapour against Clostridium difficile spores. J. Hosp. Infect. 80(1), 85-87 (2012).
61. Rutala WA, Weber DJ. Infection control: the role of disinfection and sterilization. J. Hosp. Infect. 43(Suppl.), S43-S55 (1999).
62. Nerandzic MM, Cadnum JL, Eckart KE, Donskey CJ. Evaluation of a hand-held far-ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens. BMC Infect. Dis. 12, 120 (2012).
63. Alfa MJ, Lo E, Wald A, Dueck C, DeGagne P, Harding GK. Improved eradication of Clostridium difficile spores from toilets of hospitalized patients using an accelerated hydrogen peroxide as the cleaning agent. BMC Infect. Dis. 10, 268 (2010).
64. Henriques AO, Moran CP Jr. Structure, assembly, and function of the spore surface layers. Annu. Rev. Microbiol. 61, 555-588 (2007).
65. Setlow P. I will survive: DNA protection in bacterial spores. Trends Microbiol. 15(4), 172-180 (2007).
66. Escobar-Cortes K, Barra-Carrasco J, Paredes-Sabja D. Proteases and sonication specifically remove the exosporium layer of spores of Clostridium difficile strain 630. J. Microbiol. Methods 93(1), 25-31 (2013).
67. Joshi LT, Phillips DS, Williams CF, Alyousef A, Baillie L. The contribution of the spore to the ability of Clostridium difficile to adhere to surfaces. Appl. Environ. Microbiol. 78(21), 7671-7679 (2012).
68. Barra-Carrasco J, Olgun-Araneda V, Plaza-Garrido A et al. The Clostridium difficile exosporium cystein (CdeC) rich protein is required for exosporium morphogenesis and coat assembly. J. Bacteriol. 195(17), 3863-3875 (2013).
69. Paredes-Sabja D, Sarker N, Setlow B, Setlow P, Sarker MR. Roles of DacB and Spm proteins in Clostridium perfringens spore resistance to moist heat, chemicals and UV radiation. Appl. Environ. Microbiol. 74(12), 3730-3738 (2008).
70. Cowan AE, Olivastro EM, Koppel DE, Loshon CA, Setlow B, Setlow P. Lipids in the inner membrane of dormant spores of Bacillus species are largely immobile. Proc. Natl Acad. Sci. USA 101(20), 7733-7738 (2004).
71. Setlow B, Loshon CA, Genest PC, Cowan AE, Setlow C, Setlow P. Mechanisms of killing spores of Bacillus subtilis by acid, alkali and ethanol. J. Appl. Microbiol. 92(2), 362-375 (2002).
72. Paredes-Sabja D, Setlow P, Sarker MR. Germination of spores of Bacillales and Clostridiales species: mechanisms and proteins involved. Trends Microbiol. 19(2), 85-94 (2011).
73. Setlow P. Spore germination. Curr. Opin. Microbiol. 6(6), 550-556 (2003).
74. Permpoonpattana P, Phetcharaburanin J, Mikelsone A et al. Functional characterization of Clostridium difficile spore coat proteins. J. Bacteriol. 195(7), 1492-1503 (2013).
75. Raju D, Setlow P, Sarker MR. Antisense- RNA-mediated decreased synthesis of small, acid-soluble spore proteins leads to decreased resistance of Clostridium perfringens spores to moist heat and UV radiation. Appl. Environ. Microbiol. 73(7), 2048-2053 (2007).
76. Setlow P. Small, acid-soluble spore proteins of Bacillus species: structure, synthesis, genetics, function, and degradation. Annu. Rev. Microbiol. 42, 319-338 (1988).
77. Setlow B, Setlow P. Small, acid-soluble proteins bound to DNA protect Bacillus subtilis spores from killing by dry heat. Appl. Environ. Microbiol. 61(7), 2787-2790 (1995).
78. Paredes-Sabja D, Raju D, Torres JA, Sarker MR. Role of small, acid-soluble spore proteins in the resistance of Clostridium perfringens spores to chemicals. Int. J. Food. Microbiol. 122(3), 333-335 (2008).
79. Melly E, Cowan AE, Setlow P. Studies on the mechanism of killing of Bacillus subtilis spores by hydrogen peroxide. J. Appl. Microbiol. 93(2), 316-325 (2002).
80. Mason JM, Setlow P. Essential role of small, acid-soluble spore proteins in resistance of Bacillus subtilis spores to UV light. J. Bacteriol. 167(1), 174-178 (1986).
81. Moore G, Ali S, Cloutman-Green EA et al. Use of UV-C radiation to disinfect non-critical patient care items: a laboratory assessment of the Nanoclave Cabinet. BMC Infect. Dis. 12, 174 (2012).
82. Nerandzic MM, Donskey CJ. Triggering germination represents a novel strategy to enhance killing of Clostridium difficile spores. PLoS ONE 5(8), e12285 (2010).
83. Tennen R, Setlow B, Davis KL, Loshon CA, Setlow P. Mechanisms of killing of spores of Bacillus subtilis by iodine, glutaraldehyde and nitrous acid. J. Appl. Microbiol. 89(2), 330-338 (2000).
84. Setlow B, Tautvydas KJ, Setlow P. Small, acid-soluble spore proteins of the alpha/beta type do not protect the DNA in Bacillus subtilis spores against base alkylation. Appl. Environ. Microbiol. 64(5), 1958-1962 (1998).
85. Illades-Aguiar B, Setlow P. Studies of the processing of the protease which initiates degradation of small, acid-soluble proteins during germination of spores of Bacillus species. J. Bacteriol. 176(10), 2788-2795 (1994).
86. Paredes-Sabja D, Setlow B, Setlow P, Sarker MR. Characterization of Clostridium perfringens spores that lack SpoVA proteins and dipicolinic acid. J. Bacteriol. 190(13), 4648-4659 (2008).
87. Setlow B, Atluri S, Kitchel R, Koziol-Dube K, Setlow P. Role of dipicolinic acid in resistance and stability of spores of Bacillus subtilis with or without DNA-protective alpha/beta-type small acid-soluble proteins. J. Bacteriol. 188(11), 3740-3747 (2006).
88. Francis MB, Allen CA, Shrestha R, Sorg JA. Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog. 9(5), e1003356 (2013).
89. Popham DL, Illades-Aguiar B, Setlow P. The Bacillus subtilis dacB gene, encoding penicillin-binding protein 5, is part of a three-gene operon required for proper spore cortex synthesis and spore core dehydration. J. Bacteriol. 177(16), 4721-4729 (1995).
90. Popham DL, Sengupta S, Setlow P. Heat, hydrogen peroxide, and UV resistance of Bacillus subtilis spores with increased core water content and with or without major DNA-binding proteins. Appl. Environ. Microbiol. 1(10), 3633-3638 (1995).
91. Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 63(3), 520-525 (2009).
92. Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J. Antimicrob. Chemother. 60(1), 83-91 (2007).
93. Chilton CH, Freeman J, Baines SD, Crowther GS, Nicholson S, Wilcox MH. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. J. Antimicrob. Chemother. 68(9), 2078-2082 (2013).
94. Freeman J, Marquis M, Crowther GS et al. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. J. Antimicrob. Chemother. 67(12), 2919-2926 (2012).
95. Allen CA, Babakhani F, Sears P, Nguyen L, Sorg JA. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob. Agents Chemother. 57(1), 664-667 (2013).
96. Abujamel T, Cadnum JL, Jury LA et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS ONE 8(10), e76269 (2013).
97. Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68(3), 515-522 (2013).
98. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364(5), 422-431 (2011).
99. Sorg JA, Sonenshein AL. Bile salts and glycine as co-germinants for Clostridium difficile spores. J. Bacteriol. 190(7), 2505-2512 (2008).
100. Wheeldon LJ, Worthington T, Lambert PA. Histidine acts as a co-germinant with glycine and taurocholate for Clostridium difficile spores. J. Appl. Microbiol. doi:10.1111/j.1365-2672.2011.04953.x (2011) (Epub ahead of print).
101. Heeg D, Burns DA, Cartman ST, Minton NP. Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PloS ONE 7(2), e32381 (2012).
102. Adams CM, Eckenroth BE, Putnam EE, Doubli S, Shen A. Structural and functional analysis of the CspB protease required for Clostridium spore germination. PLoS Pathog. 9(2), e1003165 (2013).
103. Paredes-Sabja D, Sarker MR. Germination response of spores of the pathogenic bacterium Clostridium perfringens and Clostridium difficile to cultured human epithelial cells. Anaerobe 17(2), 78-84 (2011).
104. Ghosh S, Setlow P. The preparation, germination properties and stability of superdormant spores of Bacillus cereus. J. Appl. Microbiol. 108(2), 582-590 (2010).
105. Nerandzic MM, Donskey CJ. Activate to eradicate: inhibition of Clostridium difficile spore outgrowth by the synergistic effects of osmotic activation and nisin. PLoS ONE 8(1), e54740 (2013).
106. Howerton A, Ramirez N, Abel-Santos E. Mapping interactions between germinants and Clostridium difficile spores. J. Bacteriol. 193(1), 274-282 (2011).